SCHEMBL6811243

SCHEMBL6811243

CCc1nn(Cc2ccccn2)c(C(N)=O)c1NC(=O)c1cc(S(C)(=O)=O)ccc1OCCOC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.40
RXFP1 Q9HBX9 4/20 0.38
IRAK4 Q9NWZ3 1/20 0.37
TERT O14746 2/20 0.37
CSF1R P07333 2/20 0.36
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 2/20 0.35
BLM P54132 1/20 0.35
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
HPGD P15428 1/20 0.34
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6799966 0.95 POLB (0.38) POLBRXFP1IRAK4TERTALDH1A1
SCHEMBL6806756 0.94 POLB (0.38) POLBRXFP1IRAK4TERTALDH1A1
SCHEMBL6806204 0.90 POLB (0.38) POLBRXFP1IRAK4TERTALDH1A1
SCHEMBL6808158 0.81 SLC6A9 (0.35) POLBIRAK4TERTLMNABLM
SCHEMBL6802097 0.77 PDE5A (0.36) POLBRXFP1IRAK4ALDH1A1HTT
SCHEMBL6801848 0.75 TERT (0.37) TERTLMNABLMADRA2ACYP2D6
SCHEMBL6806862 0.74 POLB (0.40) POLBRXFP1IRAK4ALDH1A1HTT
SCHEMBL6332714 0.73 AURKA (0.40) RXFP1KMT2AMEN1LMNAHPGD
SCHEMBL6633712 0.71 SLC6A9 (0.37) IRAK4TERTLMNABLMADRA2A
SCHEMBL6332580 0.70 PDE5A (0.57) POLBRXFP1ALDH1A1KMT2APDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6770645-B2 SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS PFIZER INC. 2004-08-03 US disclosed
US-20030064990-A1 Pharmaceutically active compounds PFIZER INC. 2003-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064990-A1 Pharmaceutically active compounds PDE5A, PDE3A, PDE2A POLB 1558/4885RXFP1 47/4885IRAK4 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.